ACHIEVE LIFE SCIENCES INC

ACHV stock represents shares of Achieve Life Sciences, Inc., a pharmaceutical company focused on developing treatments for nicotine addiction. The ticker trades on the Nasdaq Capital Market under the symbol ACHV. As a clinical-stage biopharmaceutical firm, its value is closely tied to the progress of its drug candidates. Investors often track ACHV for updates on clinical trials, regulatory milestones, and potential commercialization.

Recent performance for ACHV can be found in the price chart and performance data displayed on this page. The stock may experience significant moves based on clinical trial results, regulatory news, or financing activities. For the latest price change, volume, and percentage moves, please refer to the current ACHV quote and historical performance section available here.

Valuing ACHV is challenging because it is a clinical-stage biotech with no approved products and minimal revenue. Traditional metrics like P/E ratios are often not meaningful. Instead, investors may consider cash runway, pipeline potential, addressable market size, and comparable company analyses. For specific valuation ratios and market data, please refer to the latest figures provided on this page.

Trading activity for ACHV can vary based on news and market conditions. The stock's average daily volume and bid-ask spread are key indicators of liquidity, which are available on this page. For the most current trading data, including volume and price, please check the real-time quote displayed here.

ACHV does not currently pay dividends. As a clinical-stage biopharmaceutical company, Achieve Life Sciences typically reinvests any available capital into research and development rather than returning cash to shareholders. For the most up-to-date dividend information, please refer to the dividend section on this page.

Investing in ACHV involves substantial risks, including clinical trial failures, regulatory delays, and the need for additional capital to fund operations. As a small-cap biotech, its stock price can be highly volatile and may react sharply to news. Other risks include competition, intellectual property challenges, and dependence on key personnel. Investors should review the company's SEC filings for a detailed risk discussion.